PALI insider buying and SEC filings, explained
Palisade Bio, Inc. · CIK 1357459
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$279K
Insiders who bought
2
Sold (not marked 10b5-1)
$421K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1–2, 2026 | Purchase (code P) | Donald Allen Williams (Director) bought 20,000 shares between Oct 1 and Oct 2 at about $1.44 ($29K), reported as a purchase (code P). Holdings up 1% to 1,590,294 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 5, 2026, 5:20 PM ET |
| Jul 8–9, 2026 | Purchase (code P) | Robert Baltera Jr. (Director) bought 45,000 shares between Jul 8 and Jul 9 at about $1.97 ($89K), reported as a purchase (code P). Holdings up 11% to 461,904 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 10, 2026 |
| Jul 6–7, 2026 | Purchase (code P) | Robert Baltera Jr. (Director) bought 50,000 shares between Jul 6 and Jul 7 at about $2.04 ($102K), reported as a purchase (code P). Holdings up 14% to 416,904 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 8, 2026 |
| Jul 7, 2026 | Sale | Mitchell Lawrence Jones (Chief Medical Officer) sold 51,880 shares at about $2.05 ($106K). Holdings down 36% to 94,009 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 8, 2026 |
| Jul 7, 2026 | Sale | John David Finley (CEO and Director) sold 146,798 shares at about $2.07 ($304K). Holdings down 40% to 217,555 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 8, 2026 |
| Jul 1–2, 2026 | Purchase (code P) | Robert Baltera Jr. (Director) bought 30,000 shares between Jul 1 and Jul 2 at about $1.98 ($59K), reported as a purchase (code P). Holdings up 9% to 366,904 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 6, 2026 |
| Feb 12, 2026 | Sale | Mitchell Lawrence Jones (Chief Medical Officer) sold 1,989 shares at $1.75 ($3K). Holdings down 13% to 13,263 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Feb 12, 2026 | Sale | John David Finley (CEO and Director) sold 3,896 shares at $1.75 ($7K). Holdings down 12% to 27,353 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Jan 16, 2026 | Purchase (code P) | Donald Allen Williams (Director) bought 5,000 shares at $1.67 ($8K), reported as a purchase (code P). Holdings up 87% to 10,728 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 9, 2026 | Purchase (code P) | Donald Allen Williams (Director) bought 5,000 shares at $1.88 ($9K), reported as a purchase (code P). Holdings up 687% to 5,728 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 13, 2026 |
18 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PALI in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.